Circulating Epstein‐Barr virus microRNAs BART7‐3p and BART13‐3p as novel biomarkers in nasopharyngeal carcinoma

Abstract

EBV BamHI A rightward transcripts (BART) encode microRNAs (EBV‐miR‐BARTs) abnormally highly expressed in Nasopharyngeal carcinoma (NPC). This study aims to investigate the diagnostic and prognostic performance of miR‐BART7‐3p and miR‐BART13‐3p. Plasma levels of EBV DNA, miR‐BART7‐3p, and miR‐BART13‐3p were examined by quantitative PCR in 483 treatment‐naïve NPC patients and 243 controls without NPC. The prognostic performance was examined by comparing plasma levels with rates of distant metastasis during follow‐up. The area under the receiver operating characteristic curve for diagnosing NPC was 0.926 for EBV DNA, 0.964 for plasma miR‐BART7‐3p, 0.973 for miR‐BART13‐3p, and 0.997 for all three indices. Among 465 NPC patients without distant metastasis, the above‐median miR‐BART7‐3p and EBV‐DNA were independent risk for shorter distant metastasis‐free survival (DMFS) (HR=2.94, 95%CI: 1.44‐5.97, p=0.003; HR=2.27, 95%CI:1.26‐4.10, p=0.006) in multivariate Cox regression. EBV DNA, miR‐BART7‐3p, and miR‐BART13‐3p after radiotherapy were detectable in 28.6%, 17.6%, and 54.7% of patients, respectively. In multivariate Cox regression, detectable miR‐BART7‐3p and EBV‐DNA were independent risks for shorter DMFS (HR=4.13, 95%CI: 1.89‐9.01, p<0.001; HR = 2.14, 95%CI: 1.04‐4.42, p=0.039). Four‐years DMFS rate was 92.0% in subjects (n=156) with neither detectable miR‐BART7‐3p nor EBV DNA, 80.0% in subjects (n=65) with either detectable miR‐BART7‐3p or EBV‐DNA, and 52.9% in subjects (n=24) with both detectable miR‐BART7‐3p and EBV‐DNA after radiotherapy (p<0.001). Circulating levels of miR‐BART7‐3p and miR‐BART13‐3p show excellent diagnostic performance for NPC. The combination of plasma levels of miR‐BART7‐3p and EBV DNA at diagnosis and after radiotherapy may help stratify patients by risk of poor DMFS.